SAN DIEGO, Oct. 4, 2011 /PRNewswire/ -- Sequenom, Inc.

RICHMOND, Va., July 27 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that, effective immediately, the Company will cease the supply of IPLEX((TM)) to any new patients.

- Insmed to Evaluate Potential Initiation of Phase II Trial for IPLEX(TM) in MMD Patients with Severe Insulin Resistance - RICHMOND, Va., June 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S.

INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S. IDIS WILL HAVE RESPONSIBILITY FOR REST OF WORLD RICHMOND, Va., March 30 /PRNewswire-FirstCall/ -- Insmed Inc.

RICHMOND, Va., Jan. 21 /PRNewswire-FirstCall/ -- Insmed Inc.